Department of Health and Human Services
Public Health Service
5100 Paint Branch Parkway
May 7, 2003
VIA OVERNIGHT DELIVERY
Healthy Christian Living
395 Timber Ridge Drive
Staten Island, NY 10306
Dear Sir or Madam:
The Food and Drug Administration (FDA) has reviewed your web site at the following address: www.healthychristianliving.com. This review shows serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) in the labeling of your product Colloidal Silver. You can find the Act and implementing regulations through links on FDA’s Internet home page at www.fda.gov.
Under the Act, articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man are drugs [Section 201(g)(1)(B) of the Act]. Your web site claims that your product is useful in the treatment and prevention of Severe Acute Respiratory Syndrome (SARS). The labeling of your product bears the following claims:
“it is possible that Colloidal Silver may kill or aid in the treatment of SARS…” “antiviral, fungal, and bacterial properties of colloidal silver would assist in boosting the immune and thereby reducing the chances of infection regardless of the genesis of the microbe at work.” “… we should be taking every precaution possible to prevent the transmission of this unidentified outbreak.. .My suggestion therefore would be the following: .., Taking HCL Colloidal Silver daily…”
These claims cause your product to be a drug, as defined in section 201(g)(1)(B) of the Act. Because this product is not generally recognized as safe and effective when used as labeled, it is also a new drug as defined in section 201 (p) of the Act. Under section 505 of the Act, a new drug may not be legally marketed in the United States without an approved New Drug Application (NDA). These drugs are also misbranded within the meaning of section 502(a) of the Act because their labeling is false and misleading in that it suggests that these drugs are effective for the prevention and treatment of SARS, when, in fact, these claims are not supported by reliable scientific evidence. These drugs are also misbranded within the meaning of section 502(f)(1) of the Act, in that the labeling for these drugs fails to bear adequate directions for use.
The above violations are not meant to be an all-inclusive list of deficiencies in your products and their labeling. It is your responsibility to ensure that products marketed by your firm comply with the Act and its implementing regulations.
The Act authorizes the seizure of illegal products and injunctions against manufacturers and distributors of those products. You should take prompt action to correct these deviations and prevent their future recurrence. Failure to do so may result in enforcement action without further notice.
Please advise this office, in writing and within fifteen (15) working days of the receipt of this letter, as to the specific steps you have taken to correct the violations noted above and to assure that similar violations do not occur. If corrective actions cannot be completed within fifteen working days, state the reason for the delay and the time within which the corrections will be completed.
Jospeh R. Baca
Office of Compliance
Center for Food Safety and Applied Nutrition
This page was posted on July 9, 2005.